Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness

Future infectious disease outbreaks are inevitable; therefore, it is critical that we maximize our readiness for these events by preparing effective public health policies and healthcare innovations. Although we do not know the nature of future pathogens, antigen-agnostic platforms have the potentia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brett H. Pogostin, Kevin J. McHugh
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	adjuvants vaccines pandemic infectious disease platform technology humoral immunity Technology T Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/88eece1186a845368375618a50e7e78f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:88eece1186a845368375618a50e7e78f
record_format	dspace
spelling	oai:doaj.org-article:88eece1186a845368375618a50e7e78f2021-11-25T16:46:23ZNovel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness10.3390/bioengineering81101552306-5354https://doaj.org/article/88eece1186a845368375618a50e7e78f2021-10-01T00:00:00Zhttps://www.mdpi.com/2306-5354/8/11/155https://doaj.org/toc/2306-5354Future infectious disease outbreaks are inevitable; therefore, it is critical that we maximize our readiness for these events by preparing effective public health policies and healthcare innovations. Although we do not know the nature of future pathogens, antigen-agnostic platforms have the potential to be broadly useful in the rapid response to an emerging infection—particularly in the case of vaccines. During the current COVID-19 pandemic, recent advances in mRNA engineering have proven paramount in the rapid design and production of effective vaccines. Comparatively, however, the development of new adjuvants capable of enhancing vaccine efficacy has been lagging. Despite massive improvements in our understanding of immunology, fewer than ten adjuvants have been approved for human use in the century since the discovery of the first adjuvant. Modern adjuvants can improve vaccines against future pathogens by reducing cost, improving antigen immunogenicity, and increasing antigen stability. In this perspective, we survey the current state of adjuvant use, highlight potentially impactful preclinical adjuvants, and propose new measures to accelerate adjuvant safety testing and technology sharing to enable the use of “off-the-shelf” adjuvant platforms for rapid vaccine testing and deployment in the face of future pandemics.Brett H. PogostinKevin J. McHughMDPI AGarticleadjuvantsvaccinespandemicinfectious diseaseplatform technologyhumoral immunityTechnologyTBiology (General)QH301-705.5ENBioengineering, Vol 8, Iss 155, p 155 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	adjuvants vaccines pandemic infectious disease platform technology humoral immunity Technology T Biology (General) QH301-705.5
spellingShingle	adjuvants vaccines pandemic infectious disease platform technology humoral immunity Technology T Biology (General) QH301-705.5 Brett H. Pogostin Kevin J. McHugh Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness
description	Future infectious disease outbreaks are inevitable; therefore, it is critical that we maximize our readiness for these events by preparing effective public health policies and healthcare innovations. Although we do not know the nature of future pathogens, antigen-agnostic platforms have the potential to be broadly useful in the rapid response to an emerging infection—particularly in the case of vaccines. During the current COVID-19 pandemic, recent advances in mRNA engineering have proven paramount in the rapid design and production of effective vaccines. Comparatively, however, the development of new adjuvants capable of enhancing vaccine efficacy has been lagging. Despite massive improvements in our understanding of immunology, fewer than ten adjuvants have been approved for human use in the century since the discovery of the first adjuvant. Modern adjuvants can improve vaccines against future pathogens by reducing cost, improving antigen immunogenicity, and increasing antigen stability. In this perspective, we survey the current state of adjuvant use, highlight potentially impactful preclinical adjuvants, and propose new measures to accelerate adjuvant safety testing and technology sharing to enable the use of “off-the-shelf” adjuvant platforms for rapid vaccine testing and deployment in the face of future pandemics.
format	article
author	Brett H. Pogostin Kevin J. McHugh
author_facet	Brett H. Pogostin Kevin J. McHugh
author_sort	Brett H. Pogostin
title	Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness
title_short	Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness
title_full	Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness
title_fullStr	Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness
title_full_unstemmed	Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness
title_sort	novel vaccine adjuvants as key tools for improving pandemic preparedness
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/88eece1186a845368375618a50e7e78f
work_keys_str_mv	AT bretthpogostin novelvaccineadjuvantsaskeytoolsforimprovingpandemicpreparedness AT kevinjmchugh novelvaccineadjuvantsaskeytoolsforimprovingpandemicpreparedness
_version_	1718412968406810624

Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness

Ejemplares similares